Phase II trial of chronic daily VP-16 administration in unresectable hepatocellular carcinoma (HCC).

R Wierzbicki; A Ezzat; A Abdel-Warith; A Ayoub; I Kagevi; M Fadda; J Sieck; M Abdulkareem; T Amin; A Yazigi

doi:10.1093/oxfordjournals.annonc.a058882

Phase II trial of chronic daily VP-16 administration in unresectable hepatocellular carcinoma (HCC).

Identifier:nobleid.org/w1/20260515/FE76C40B

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/FE76C40B.svg?ark=w1%2F20260515%2FFE76C40B)](https://nobleid.org/work/w1/20260515/FE76C40B)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Phase II trial of chronic daily VP-16 administration in unresectable hepatocellular carcinoma (HCC).

Identifier:nobleid.org/w1/20260515/FE76C40B

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/FE76C40B.svg?ark=w1%2F20260515%2FFE76C40B)](https://nobleid.org/work/w1/20260515/FE76C40B)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work